Cancer

Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture

Neoplasms, Cancer, Melanoma, Fibrosarcoma, Health, Medicine
Thursday, May 13, 2021 - 9:02pm

Kinnate Biopharma will be the majority shareholder in the joint venture.

Key Points: 
  • Kinnate Biopharma will be the majority shareholder in the joint venture.
  • KIN-2787 is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor candidate being developed for the treatment of patients with lung cancer, melanoma, and other solid tumors.
  • The joint venture will also pursue development of KIN-3248 for the Chinese market.
  • Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

American Skin Association Announces 2021 Research Grants for Skin Cancer and Diseases

Academic journals, Cancer, Melanoma, Medical education, Skin cancer, Publications
Thursday, May 13, 2021 - 5:17pm

b'NEW YORK, May 13, 2021 /PRNewswire/ -- American Skin Association has announced the awarding of two coveted research grants under the ASA Milstein Research Scholar Awards program.

Key Points: 
  • b'NEW YORK, May 13, 2021 /PRNewswire/ -- American Skin Association has announced the awarding of two coveted research grants under the ASA Milstein Research Scholar Awards program.
  • The Stiefel Family, longtime supporters of ASA, generously contributed $300,000 to support grants for melanoma research.
  • The purpose of this funding is to identify and support emerging leaders in dermatology focused on melanoma research.
  • With an exclusive focus on skin disease research, ASA has helped open new frontiers in skin science, producing results that can change how we understand and treat skin disease.\nThe following are the recipients of the 2021 Investigative Scientist Award, Research Scholar Awards, Research Grants, and Medical Student Grants:\nA unique collaboration of patients, families, advocates, physicians, and scientists, ASA has evolved over three decades as a leading force in efforts to defeat melanoma, skin cancer, and other skin diseases.

Global Bone Cancer Markets, Epidemiology and Patient Flow Report 2020-2035 - ResearchAndMarkets.com

Pharmaceutical, Health, Oncology, Musculoskeletal system, Carcinogenesis, Epidemiology of cancer, Branches of biology, Medication-related osteonecrosis of the jaw, Bone, Cancer, Paget's disease of bone
Thursday, May 13, 2021 - 2:09pm

b'The "Global Bone Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Bone Cancer Epidemiology and Patient Flow Analysis - 2021, provides Bone Cancer epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Bone Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Bone Cancer Epidemiology and Patient Flow Analysis - 2021, provides Bone Cancer epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Bone Cancer patients, history of the disease at the population level (Bone Cancer prevalence, Bone Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Bone Cancer patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Bone Cancer market sizing, assessing market potential, and developing drug forecast models\nIdentify Bone Cancer patients segments through age groups, gender, and disease sub-types\nEvaluate Bone Cancer market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210513005624/en/\n'

AIkido Pharma Inc.: Invitation to the Q2 Virtual Investor Summit

Cancer, Life sciences, Companies, Health sciences
Thursday, May 13, 2021 - 2:00pm

b"AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics.

Key Points: 
  • b"AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics.
  • Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer.
  • We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.
  • The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.\n"

Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial

Lung cancer, Pancreatic cancer, Non-small-cell lung carcinoma, Adenocarcinoma, Cancer, Neoplasms, Clinical medicine
Thursday, May 13, 2021 - 1:00pm

In the collaborations, Merus plans to support molecular screenings for eligible patients with pancreatic adenocarcinoma in Israel and Italy, and with non-small cell lung cancer (NSCLC) in Spain, aimed to identify the presence of NRG1 fusions.

Key Points: 
  • In the collaborations, Merus plans to support molecular screenings for eligible patients with pancreatic adenocarcinoma in Israel and Italy, and with non-small cell lung cancer (NSCLC) in Spain, aimed to identify the presence of NRG1 fusions.
  • plans to perform a nationwide campaign in Israel to raise awareness of the molecular screening offered by Merus for eligible pancreatic adenocarcinoma patients and availability of the eNRGy trial for eligible patients.
  • The Cl\xc3\xadnica Universidad de Navarra, based in Pamplona and Madrid, is a leading research hospital in Spain.
  • The eNRGy trial consists of three cohorts: NRG1+ pancreatic cancer; NRG1+ non-small cell lung cancer; and NRG1+ other solid tumors.

Insights on the Thyroid Cancer Diagnostics Global Market to 2028 - Share, Size, Trends and Industry Analysis Report - ResearchAndMarkets.com

Biotechnology, Health, Oncology, Anatomy, Thyroid disease, Organ systems, Branches of biology, Thyroid cancer, Thyroid, Cancer, Papillary thyroid cancer
Thursday, May 13, 2021 - 12:41pm

b'The "Thyroid Cancer Diagnostics Market Share, Size, Trends, Industry Analysis Report, By Type; By Technique; By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global thyroid cancer diagnostics market size is expected to reach USD 3.84 billion by 2028 according to a new study.

Key Points: 
  • b'The "Thyroid Cancer Diagnostics Market Share, Size, Trends, Industry Analysis Report, By Type; By Technique; By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global thyroid cancer diagnostics market size is expected to reach USD 3.84 billion by 2028 according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.\nThe high prevalence rate of thyroid cancer in the market, huge unmet medical needs, drug approvals, and research initiatives to deal with early diagnosis are the prominent drivers responsible for the market growth.
  • It is being estimated that each year, around 53,000 people in the U.S. alone expected to diagnose with thyroid cancer.
  • RET-activated mutations are key instigators in many cancer forms, including thyroid cancers.

Osmol Therapeutics Initiates IND Enabling Studies to Develop First Therapy for Prevention of Chemotherapy-Induced Peripheral Neuropathy

Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Cancer, Chemotherapy, Oncology, Chemotherapy-induced peripheral neuropathy, Taxane, Breast cancer, Causes of cancer pain
Thursday, May 13, 2021 - 12:30pm

b'Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN).

Key Points: 
  • b'Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN).
  • OSM-0205\xe2\x80\x99s mechanism addresses the off-target toxicity of microtubule-based chemotherapy agents that results in a calcium surge leading to CIPN.
  • Taxanes are the most widely used chemotherapy treatment for breast cancer and can lead to CIPN in up to 80% of patients.
  • The company\xe2\x80\x99s lead indication will be for the prevention of CIPN in breast cancer patients treated with taxane-based therapy, a treatment regimen in which up to 80% of patients experience CIPN.

LET'S WIN! PANCREATIC CANCER Turns 5!

Lustgarten Foundation for Pancreatic Cancer Research, Pancreatic cancer, Cancer
Thursday, May 13, 2021 - 12:55pm

Pancreatic Cancer launched its unprecedented platform to fill a void for pancreatic cancer patients.

Key Points: 
  • Pancreatic Cancer launched its unprecedented platform to fill a void for pancreatic cancer patients.
  • Let\'s Win also introduces experienced physicians who do not specialize in pancreatic cancer to emerging treatments to combat the disease.
  • The Let\'s Win Scientific Advisory Board is comprised of world-renowned scientists and physicians who lead cutting-edge research on pancreatic cancer.
  • Pancreatic Cancer is a 501(c)(3) organization and is proud to be an affiliate of the Lustgarten Foundation.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/lets-win-pancreatic-cancer-turns...\n'

PDS Biotech Provides Business Update and Reports First Quarter 2021 Financial Results

Cancer, Clinical medicine, Medicine, Virotherapy, Cancer immunotherapy, Immunotherapy, Human papillomavirus infection
Thursday, May 13, 2021 - 12:00pm

Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotech.

Key Points: 
  • Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotech.
  • PDS Biotech has developed multiple therapies, based on combinations of Versamune\xc2\xae and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them.
  • The Company\xe2\x80\x99s lead investigational cancer immunotherapy product PDS0101 is currently in Phase 2 clinical studies in HPV-associated cancers.
  • Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance.

Genetron Health Announces Strategic Partnership with Siemens Healthineers to Promote Precision Oncology for Lung Cancer

Oncology, Health, Hospitals, General Health, Clinical trials, Research, Science, Cancer, Siemens Healthineers, Targeted therapy, Oncology, Lung cancer, Health, Medicine, Draft:Genetron Health
Thursday, May 13, 2021 - 11:20am

\xe2\x80\x9cWe are pleased to collaborate with Siemens Healthineers for our S5 instrument and lung 8 IVD assay, which helps diagnose and treat cancer patients.

Key Points: 
  • \xe2\x80\x9cWe are pleased to collaborate with Siemens Healthineers for our S5 instrument and lung 8 IVD assay, which helps diagnose and treat cancer patients.
  • We are excited to forge a strategic partnership with Genetron Health, an industry leading precision oncology platform company.
  • In China, 787,000 cases of lung cancer are diagnosed every year, with about 631,000 deaths [1] caused annually as well.
  • As the "first step" of targeted therapy for lung cancer, cancer molecular gene detection is the key to guided clinical treatment and drug applications.